Soliton Stock Rallies After $22.60/Share Buyout From AbbVie

Monday, 10 May 2021, 16:27:56
AbbVie Inc (NYSE: ABBV ) is making an opportunistic play to boost the aesthetics business by adding a long-delayed body sculpting product into the fold. AbbVie’s Allergan Aesthetics unit will pay $550 million in cash to scoop up Soliton Inc (NASDAQ: SOLY ) and Resonic, its sound-wave device that improves the appearance of cellulite. Under the terms of the transaction, Allergan Aesthetics will pay $22.60 per … Full story available on Benzinga.com
— Benzinga

The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data

Tuesday, 4 May 2021, 14:10:20
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV ) BioNTech SE – ADR (NASDAQ: BNTX ) (moving on momentum imparted by vaccine news flow) GT Biopharma Inc (NASDAQ: GTBP ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Lantheus Holdings Inc (NASDAQ: LNTH ) Orthopediatrics Corp (NASDAQ: KIDS ) Quest Diagnostics Incorporated (NYSE: DGX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aptinyx Inc. (NASDAQ: APTX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AVROBIO, Inc. (NASDAQ: AVRO ) (reacted to the need for conducting a registrational trial for its gene therapy candidate for Fabry disease) Aziyo Biologics, Inc. (NASDAQ: AZYO ) Celyad Oncology SA (NASDAQ: CYAD ) Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ) Decibel Therapeutics, Inc.
— Benzinga

AbbVie Beats Q1 Earnings On Strong Humira Sales, Raises Full-Year Profit Forecast

Friday, 30 April 2021, 15:17:48
AbbVie Inc (NYSE: ABBV ) beat Wall Street consensus for first-quarter revenue & earnings and raised its full-year profit forecast, helped by demand for its rheumatoid arthritis drug, Humira, and newer treatments such as psoriasis treatment Skyrizi. It reported an adjusted EPS of $2.95, which beat the analyst consensus estimate of $2.83 Sales of $13.01 billion also surpassed the analyst consensus estimate of $12.76 billion and increased 50% over sales of $8.62 … Full story available on Benzinga.com
— Benzinga

Abbvie Posts First-Quarter Earnings Beat and Raises Guidance – TheStreet

Friday, 30 April 2021, 14:03:49
AbbVie reports first-quarter earnings that beat expectations and raises its full-year outlook amid stronger-than-expected sales of its therapeutic drugs and treatments.
— The Street

AbbVie raises full-year profit forecast as Humira fuels sales beat

Friday, 30 April 2021, 13:55:28
https://www.investing.com/news/stock-market-news/abbvie-raises-fullyear-profit-forecast-as-humira-fuels-sales-beat-2491276
— Investing.com